Will FDA inspect ongoing international clinical trials?

A June 2010 report by the HHS Office of Inspector General raises two issues:  FDA’s inability to inspect active foreign clinical trial sites, and the growing trend of firms conducting clinical trials overseas.  What is the likelihood we’ll see the four key recommendations in the report adopted? Continue reading at ComplianceZen.com →